PS02.030: CLINICAL COURSE OF PATIENTS WITH COMPLETE RESPONSE BY CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGIEAL CANCER

Abstract

Abstract Background Definitive chemoradiotherapy (dCRT) is one of the treatment strategies for patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). In this report, we investigated the timing, pattern of recurrence, and prognosis in patients with LA-ESCC who achieved clinical complete response (cCR) following dCRT. Methods dCRT was performed for 71 patients with LA-ESCC from April 2006 and December 2017. We retrospectively examined the clinical records of 27 patients (38%) with ESCC who achieved cCR following dCRT assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). These patients were classified into two groups: 19 patients (Group A) who did not recognize recurrence thereafter and 8 cases (Group B) who were confirmed to have recurred until Deccember 2017. Clinicopathological features and clinical course for two groups were examined. Results Clinical stages before treatment were cT1/2/3/4 = 7/3/6/3 cases, cN0/1/2/3 = 8/3/6/2, cM0/1 = 18/1 and cStage I/II/III/IV = 6/4/6/3 in Group A, and cT1/2/3/4 = 1/3/2/2, cN0/1/2/3 = 1/2/4/1, cM0/1 = 8/0, cStage I/II/III/IV = 1/0/5/2 in Group B, respectively. Patients in Group B had more advanced cases than Group A. In group A, 16 out of 19 patients (84%) are still alive without recurrence and 3 have died because of hypopharyngial cancer, lung cancer, and senility, respectively. Double cancers were confirmed in 12 patients (63%) including 6 head and neck cancers. In Group B, the recurrences were confirmed at 7–26 months (Median: 12.5M) from the diagnosis of cCR. Six out of 8 patients (6/8:75%) had the recurrence of mediastinal lymph nodes. In Group B, 6 out of 8 cases (75%) confirmed death, and the period from recurrence to death was 5–18 months (median: 9.5M). Conclusion After cCR was obtained by dCRT, recurrence was observed in 8/27 cases (29.6%) in about 13 months. In patients with recurrence, 75% of patients had mediastinal lymph node recurrence and had poor prognosis of about 10 months. Also in patients without recurrence, double cancers were observed in 12/19 cases, suggesting the importance of surveillance for the purpose of 2nd primary cancer screening. Disclosure All authors have declared no conflicts of interest.